drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD19 on B-lineage malignant cells; used for CD19-positive lymphoproliferative disorders. CAR engagement triggers T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes CD19 on B-lineage malignant cells; CAR engagement triggers CD3ΞΆ and costimulatory signaling (e.g., CD28 or 4-1BB), leading to T-cell activation, proliferation, cytokine release, and targeted cytotoxic killing of CD19-positive cancer cells.
drug_name
CD19-directed CAR T cells
nct_id_drug_ref
NCT06630104